How old is patient?
What is Moxifloxacin-ratiopharm?
Moxifloxacin-ratiopharm is a fluoroquinolone (flor-o-KWIN-o-lone) antibiotic that fights bacteria in the body.
Moxifloxacin-ratiopharm ophthalmic (for use in the eyes) is used to treat bacterial infections of the eyes.
Moxifloxacin-ratiopharm will not treat a viral or fungal infection of the eye. This medicine is for use in treating only bacterial infections.
Moxifloxacin-ratiopharm ophthalmic may also be used for purposes not listed in this medication guide.
Acute Bacterial Sinusitis
Moxifloxacin-ratiopharm hydrochloride tablets are indicated in adult patients (18 years of age and older) for the treatment of Acute Bacterial Sinusitis caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.
Acute Bacterial Exacerbation of Chronic Bronchitis
Moxifloxacin-ratiopharm hydrochloride tablets are indicated in adult patients for the treatment of Acute Bacterial Exacerbation of Chronic Bronchitis caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis.
Community Acquired Pneumonia
Moxifloxacin-ratiopharm hydrochloride tablets are indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug resistant Streptococcus pneumoniae [MDRSP]),Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae.
MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.
Uncomplicated Skin and Skin Structure Infections
Moxifloxacin-ratiopharm hydrochloride tablets are indicated in adult patients for the treatment of Uncomplicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.
Complicated Skin and Skin Structure Infections
Moxifloxacin-ratiopharm hydrochloride tablets are indicated in adult patients for the treatment of Complicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae.
Complicated Intra-Abdominal Infections
Moxifloxacin-ratiopharm hydrochloride tablets are indicated in adult patients for the treatment of Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by susceptible isolates of Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species.
Moxifloxacin-ratiopharm hydrochloride tablets are indicated in adult patients for the treatment of plague, including pneumonic and septicemic plague, due to susceptible isolates of Yersinia pestis and prophylaxis of plague in adult patients. Efficacy studies of Moxifloxacin-ratiopharm could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Moxifloxacin-ratiopharm hydrochloride tablets and other antibacterial drugs, Moxifloxacin-ratiopharm hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Moxifloxacin-ratiopharm?
Use Moxifloxacin-ratiopharm as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Moxifloxacin-ratiopharm comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Moxifloxacin-ratiopharm refilled.
- Take Moxifloxacin-ratiopharm by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.
- Drink plenty of liquids while taking Moxifloxacin-ratiopharm.
- Do not take a product that has magnesium, aluminum, calcium, zinc, iron, or sucralfate in it within 8 hours before or 4 hours after you take Moxifloxacin-ratiopharm. Examples of these products include antacids, multivitamins, chewable/buffered didanosine, didanosine suspension, and quinapril. Check with your doctor or pharmacist if you have a question about whether you should separate Moxifloxacin-ratiopharm from a certain food or product.
- Take Moxifloxacin-ratiopharm on a regular schedule to get the most benefit from it.
- To clear up your infection completely, take Moxifloxacin-ratiopharm for the full course of treatment. Keep taking it even if you feel better in a few days.
- If you miss a dose of Moxifloxacin-ratiopharm, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take more than 1 dose in the same day.
Ask your health care provider any questions you may have about how to use Moxifloxacin-ratiopharm.
Uses of Moxifloxacin-ratiopharm in details
Moxifloxacin-ratiopharm is used to treat bacterial infections of the respiratory tract, infections of female upper genital tract, abdominal infections and infections of skin and eye.
Each tablet contains Moxifloxacin-ratiopharm HCl 436.8 mg equivalent to Moxifloxacin-ratiopharm 400 mg. It also contains croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, hypromellose, macrogol 4000, titanium dioxide (E171) and ferric oxide (E172) as inactive constituents.
Each 250 mL solution for infusion contain Moxifloxacin-ratiopharm HCl 436.8 mg equivalent to Moxifloxacin-ratiopharm 400 mg. It also contains sodium chloride, 1N hydrochloric acid, 2N sodium hydroxide and water for injection. The solution for infusion (250 mL) contains sodium 34 mmol.
Active ingredient matches for Moxifloxacin-ratiopharm:
Moxifloxacin in Germany, Hungary.
- Wikipedia. "moxifloxacin: Link to the compound information in Wikipedia.". https://en.wikipedia.org/wiki/Moxifloxac... (accessed September 18, 2017).
- PubChem. "moxifloxacin". https://pubchem.ncbi.nlm.nih.gov/compoun... (accessed September 18, 2017).
- FDA Orange Book. "Patent:9114168: The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).". https://www.fda.gov/Drugs/InformationOnD... (accessed September 18, 2017).
ReviewsThe results of a survey conducted on ndrugs.com for Moxifloxacin-ratiopharm are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Moxifloxacin-ratiopharm. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
Consumer reported ageNo survey data has been collected yet